Approval

FDA Approves Venglustat

Sanofi announced FDA approval of venglustat for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, describing it as the first US treatment for those symptoms. In the 43-patient phase 3 LEAP2MONO trial, venglustat showed a significant neurological benefit over imiglucerase; platelet count did not meet the noninferiority criterion. Venglustat is under review in the EU, and Sanofi plans further submissions in other regions in 2026.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call